Article
China Approves World's First Denosumab Biosimilar
Luye Pharma Group announced last week that China's National Medical Products Administration has approved a marketing launch of BOYOBEI® for treatment of postmenopausal women with osteoporosis at high risk of fractures.
Goodwin Procter LLP